Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 186

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Crizotinib in MET -Deregulated or ROS1 -Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

Open access
Landi, Lorenza, Chiari, Rita, Tiseo, Marcello, D'Incà, Federica, Dazzi, Claudio, Chella, Antonio, Delmonte, Angelo, Bonanno, Laura, Giannarelli, Diana, Cortinovis, Diego Luigi, de Marinis, Filippo, Borra, Gloria, Morabito, Alessandro, Gridelli, Cesare, Galetta, Domenico, Barbieri, Fausto, Grossi, Francesco, Capelletto, Enrica, Minuti, Gabriele, Mazzoni, Francesca, Verusio, Claudio, Bria, Emilio, Alì, Greta, Bruno, Rossella, Proietti, Agnese, Fontanini, Gabriella, Crinò, Lucio, Cappuzzo, Federico · 2019 · Clinical Cancer Research

Abstract

Purpose: MET-deregulated NSCLC represents an urgent clinical need because of unfavorable prognosis and lack of specific therapies. Although recent studies have suggested a potential role for crizotinib in patients harboring MET amplification or exon 14 mutations, no conclusive data are currently available. This study aimed at investigating activity of crizotinib in patients harboring MET or ROS1 alterations. Patients and Methods: Patients with pretreated advanced NSCLC and evidence of ROS1 rearrangements (cohort A) or MET deregulation (amplification, ratio MET/CEP7 >2.2 or MET exon 14 mutations, cohort B) were treated with crizotinib 250 mg twice daily orally. The coprimary endpoint was objective response rate in the two cohorts. Results: From December 2014 to March 2017, 505 patients were screened and a total of 52 patients (26 patients per cohort) were enrolled onto the study. At data cutoff of September 2017, in cohort A, objective response rate was 65%, and median progression-free survival and overall survival were 22.8 months [95% confidence interval (CI) 15.2–30.3] and not reached, respectively. In cohort B, objective response rate was 27%, median progression-free survival was 4.4 months (95% CI 3.0–5.8), and overall survival was 5.4 months (95% CI, 4.2–6.5). No difference in any clinical endpoint was observed between MET-amplified and exon 14–mutated patients. No response was observed among the 5 patients with cooccurrence of a second gene alteration. No unexpected toxicity was observed in both cohorts. Conclusions: Crizotinib induces response in a fraction of MET-deregulated NSCLC. Additional studies and innovative therapies are urgently needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-0994

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 186

Metadata

Authors
Landi, L., Chiari, R., Tiseo, M., D'Incà, F., Dazzi, C., Chella, A., Delmonte, A., Bonanno, L., Giannarelli, D., Cortinovis, D. L., de Marinis, F., Borra, G., Morabito, A., Gridelli, C., Galetta, D., Barbieri, F., Grossi, F., Capelletto, E., Minuti, G., Mazzoni, F., Verusio, C., Bria, E., Alì, G., Bruno, R., Proietti, A., Fontanini, G., Crinò, L., & Cappuzzo, F.
Venue
Clinical Cancer Research
Published
2019-12-13
Volume
25
Issue
24
Pages
7312-7319
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2967992516
Cited by
186
References
5
FWCI
17.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Crizotinib in MET -Deregulated or ROS1 -Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0994
The paper
Landi, L., Chiari, R., Tiseo, M., D'Incà, F., Dazzi, C., Chella, A., Delmonte, A., Bonanno, L., Giannarelli, D., Cortinovis, D. L., de Marinis, F., Borra, G., Morabito, A., Gridelli, C., Galetta, D., Barbieri, F., Grossi, F., Capelletto, E., Minuti, G., . . . Cappuzzo, F. (2019). Crizotinib in MET -Deregulated or ROS1 -Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0994

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.